Similar to the PD-1/PD-L1 pathway, cancer cells can exploit the CTLA-4 pathway to evade immune destruction by upregulating the expression of B7 ligands or expressing soluble CTLA-4, thus suppressing T cell activity and promoting tumor immune evasion (118). This evidence concerns the gene PDCD1 and neoplasm.